Artifical intelligence technology in cancer imaging: Clinical challenges for detection of lung and breast cancer by COCCIA, Mario
Journal of 
Social and Administrative Sciences 
www.kspjournals.org 
Volume 6                          June 2019                              Issue 2 
 
Artifical intelligence technology in cancer imaging: 
Clinical challenges for detection of lung and breast 
cancer 
 
By Mario COCCIAa† 
 
Abstract. In the domain of Artificial Intelligence, deep learning is part of a broader family of 
machine learning methods based on deep neural networks, deep belief networks, recurrent 
neural networks and convolutional neural networks that have been applied to fields 
including computer vision, medical image analysis, histopathological diagnosis, with results 
comparable to and in some cases superior to human experts. This study shows that these 
methods applied to medical imaging can assist pathologists in the detection of cancer 
subtype, gene mutations and/or metastases for applying appropriate therapies. Results 
show that trajectories of AI technology applied in cancer imaging seems to be driven by 
high rates of mortality of some types of cancer in order to improve detection and 
characterization of cancer to apply efficiently anticancer therapies. This new technology can 
generate a technological paradigm shift for diagnostic assessment of any cancer type. 
However, application of these methods to medical imaging requires further assessment and 
validation to support the efficiency of the workflow of pathologists in clinical practice and 
improve overall healthcare sector.  
Keywords. Artificial intelligence, Diagnostic assessment, Histopathology images, Deep 
learning algorithms, Cancer, Clinical challenges. 
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1. Introduction  
rtificial Intelligence (AI) is the research field that studies and 
develops technological systems that can solve complex tasks in 
ways that would traditionally need human intelligence (Iafrate, 
2018). This new technology, originated from interaction between 
engineering, computer science and other applied sciences, is developing 
main fields of applied research with technology transfer in robotics, natural 
language processing, machine learning, computer vision, etc. The artificial 
intelligence can be the source of a self-propagating development of 
technology that acquiring new functionality from digital industry and 
information and communication technology, it can generate a vast 
industrial and social change in economic systems (cf., Geuna et al., 2017). In 
this domain of AI, Machine Learning (ML) has made a tremendous 
progress over the last decades. Many scholars believe that ML is capable of 
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making progress on any real-world problem. In the research field of 
machine learning, deep learning is a family of computational methods that 
allow an algorithm to program itself by learning from a large set of 
examples that demonstrate the desired behavior, removing the need to 
specify rules explicitly (cf., Goodfellow et al., 2018).  
In this context, the paper here shows the first applications of AI 
technology to cancer imaging that can generate a technological paradigm 
shift in oncology for improving diagnostics and accelerating treatments of 
these diseases (cf., Kantarjian & Yu, 2015; Li et al., 2019). This study focused 
on case studies of new deep learning algorithms for detection of lung and 
breast cancer that are two of the most important diseases in society. These 
case studies can show the high potential of path-breaking applications of 
AI in medicine that can generate an industrial and social change in clinics. 
Moreover, this study analyses the comparative evolutionary pathways of 
this emerging technology for three critical cancers (lung, breast and 
thyroid) to explain possible drivers. A discussion shows socioeconomic 
barriers to the diffusion of this new technology in medicine that can be 
generalized for explaining the dynamics of this new technology in 
medicine and next applications in other sectors of economic system. 
 
2. Background 
Artificial Intelligence (AI) is the research field that studies and develops 
technological systems that can solve complex tasks in ways that would 
traditionally need human intelligence. The artificial intelligence can 
generate a vast industrial and social change in economic systems (cf., 
Geuna et al., 2017).  
In this domain of AI, Machine learning (ML) is the scientific study of 
algorithms and statistical models that computer systems use to effectively 
perform a specific task without using explicit instructions, relying on 
patterns and inference instead (Fig. 1). Machine learning algorithms build a 
mathematical model based on sample data, known as "training data", in 
order to make predictions or decisions without being explicitly 
programmed to perform the task.  
Deep learning is part of a broader family of machine learning methods 
based on artificial neural networks (Madabhushi et al., 2016). Deep learning 
architectures such as deep neural networks, deep belief networks, recurrent 
neural networks and convolutional neural networks have been applied to 
fields including computer vision, speech recognition, natural language 
processing, audio recognition, social network filtering, machine translation, 
bioinformatics, drug design, medical image analysis, histopathological 
diagnosis, material inspection and board game programs, where they have 
produced results comparable to and in some cases superior to human 
experts (Litjens et al., 2016).  
This new technology, in particular, deep learning algorithms can be 
applied for improving diagnostic accuracy and efficiency of detection of 
cancer.  
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Figure 1. Artificial Intelligence and it main research fields 
 
Cancer is an organism which lives off a host organ, growing by bio-
genetic-molecular mechanism. 9.6 million people died of cancer in 2018 – 
more than from HIV/AIDS, malaria and tuberculosis combined. The 
incidence of cancer is estimated to double by 2035, with most of these cases 
expected to occur in low-to-middle income countries (LMICs). 60% of 
cancer cases occur in LMICs, and 75% cancer deaths occur in these 
countries (Prager, ‎2018). In many LMICs, breast cancer remains the leading 
malignancy affecting women and the leading cause of cancer-related deaths 
(Bray et al., 2018).  
Table 1 shows that lung and breast cancer have the highest mortality 
rate worldwide (cf. also Parkin et al., 2005).  
 
Table 1. Incidence and mortality of big 8 cancers in 2018, worldwide, both sexes, all ages 
Cancer 
Incidence Mortality 
ASR (W)* ASR (W)* 
 Lung 22.5 18.6 
 Breast 46.3 13.0 
 Colorectum 19.7 8.9 
 Prostate 29.3 7.6 
 Stomach 11.1 8.2 
 Pancreas 4.8 4.4 
 Ovary 7.8 3.9 
 Liver 9.3 8.5 
Note: Age-Standardized Rate-ASR (W): A rate is the number of new cases or deaths per 100,000 persons 
per year. An age-standardized rate is the rate that a population would have if it had a standard age 
structure.  
Source. World Health Organization, International Agency for Research on Cancer (2019).  
 
The R&D in oncology is supporting the convergence of different 
research fields, such as genetics 1 , genomics 2 , nanotechnology, 
1 Genetics studies the molecular structure and function of genes in the context of a cell or 
organism. 
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nanomedicine, computer sciences, etc., that are generating new 
technological pathways for diagnostics and therapeutics (Coccia, 2014, 
2016). Clinical challenges are in the accurate detection and characterization 
of cancers. In particular, artificial intelligence (AI), generated by converging 
technologies in applied sciences, can support the qualitative interpretation 
of cancer imaging by expert clinicians, such as volumetric delineation of 
tumors as well as evaluation of the impact of disease and treatment on 
adjacent organs. In general, AI may automate processes in the initial 
interpretation of images and shift the clinical workflow on high-level 
decisions to efficiently apply anti-cancer treatments for patients. 
 
2.1. The goal of this investigation 
The purpose of this study is to show the potential of Artificial 
Intelligence Technology in cancer imaging to distinguish between cancer, 
metastases or normal lung tissue. This study shows two case study of 
clinical challenges and applications of AI in lung and breast cancer. 
Moreover, this study endeavors to analyze evolutionary pathways of this 
AI for three critical cancers (lung, breast and thyroid) to explain possible 
drivers. 
  
2.2. Importance 
Importance of the paper here is to show that this emerging technology 
applied in medicine shows increasingly concerted efforts in pushing AI 
technology to clinical use and to impact future directions in cancer care, 
although most studies evaluating AI applications in oncology to medical 
imaging requires further assessment and validation for reproducibility and 
generalizability of results. 
 
3. Material and Methods: Study design and setting 
In order to show the potential of deep learning algorithms in cancer imaging, 
this study describes two case studies of AI technology applied for detection and 
characterization of lung cancer and lymph node metastases in women breast cancer. 
Moreover, to show the evolutionary pathways of AI technology and deep 
learning in the research field of cancer, this study considers data from Science Direct 
(2019) using the tool Advanced Search to find articles that have in title, abstract or 
keyword the following terms: 
• Artificial intelligence and lung cancer 
• Artificial intelligence and breast cancer 
• Artificial intelligence and thyroid cancer 
• Deep learning and lung cancer 
• Deep learning and breast cancer 
• Deep learning and thyroid cancer 
2 Genomics is a discipline in genetics that studies the genomes of organisms. In particular, it 
determines the entire DNA sequence of organisms and fine-scale genetic mapping efforts. 
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The evolution of AI technology in cancer settings is measured with the number 
of articles from 1996 to 2018 for a comparative analysis of the trends of three 
different types of cancer (lung, breast and thyroid).The visual representation of 
trends is also used to detect the most appropriate model to estimate the relation of 
number of articles over time and assess the evolutionary growth of this new 
technology between different research fields of oncology. 
The relation between number of articles per years of AI applied in cancer 
imaging of different cancers is estimated with regression analysis (Ordinary Least 
Squares Method) using an exponential model. Outputs of statistical analysis are:  
regression coefficients, adjusted R2, standard error of the estimate and analysis-of-
variance table. 
In order to assess the evolutionary growth of AI technology applied to specific 
types of cancer (lung, breast and thyroid cancer) the following exponential equation 
is applied over 1996-2018 period: 
 
𝑃𝑃𝑡𝑡(2018)=𝑃𝑃0(1996) 𝑒𝑒𝑟𝑟𝑡𝑡  
 
P= number of articles with a combination of keywords 
 
𝑃𝑃𝑡𝑡
𝑃𝑃0=𝑒𝑒𝑟𝑟𝑡𝑡  
𝐿𝐿𝐿𝐿𝐿𝐿 �
𝑃𝑃𝑡𝑡
𝑃𝑃0�=𝑟𝑟 ∙ 𝑡𝑡  
𝒓𝒓 =  𝐿𝐿𝐿𝐿𝐿𝐿 �𝑃𝑃𝑡𝑡𝑃𝑃0�
𝑡𝑡
 
 
A comparative analysis of results can suggest the direction and intensity 
of acceleration of technological trajectories of AI technology in different 
cancer settings and possible drivers. 
 
4. Results: case studies and evolution of AI technology in 
cancer imaging 
Artificial Intelligence and deep learning for detecting the typology of lung 
cancer: A revolution in medicine 
Lung cancer is one of the main diseases in several countries and a 
leading cause of cancer death – both sexes – worldwide. Lung cancer is 
linked to several risk factors in society, such as smoking, passive smoking, 
air pollution, etc. Lung cancer can be either small cell lung cancer or no 
small cell lung cancer (NSCLC), with the latter representing about 80% of 
the cases. The mortality of lung cancer is very high and the five-year 
survival rate of patients is about 2–10% (Coccia, 2014, 2012). The detection 
of the type of lung cancer (e.g., adenocarcinoma, squamous cell carcinoma, 
etc.), mutations (e.g., EGFR: epidermal growth factor receptor; ALK: 
anaplastic lymphoma receptor tyrosine kinase rearrangements) and 
sequential mutations (T790) is a critical process in diagnostics to select the 
appropriate therapy that can be conventional chemotherapies, target 
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therapies such as gefitinib, erlotinib, etc., or new immune therapies, e.g., 
nivolumab, atezolizumab (cf., Coccia, 2014). This critical process affects the 
survival of patients (cf., Fig. 2).  
 
 
Figure 2. Roadmap for Non-small lung cancer treatments based on EGF-R blocking 
agents. 
Source: Dempke et al., (2010), Lung Cancer, 67, p.265. 
 
Classification and mutation of lung cancer type is a critical diagnostic 
process because the available treatment options, including conventional 
chemotherapy and, more recently, targeted therapies, differ for lung 
adenocarcinoma and lung squamous cell carcinomas.  
Current technology for an accurate diagnosis and selection of treatment 
options is based on molecular biomarkers applied on lung biopsies and/or blood 
testing: this approach can diagnose lung cancer type and stage. This current 
technology has some negative effects. On the one side, patients have to 
receive an invasive surgical intervention for tissue biopsies or to do liquid 
biopsy (e.g., blood) and wait a certain time (about a month) before to have 
the diagnosis of cancer type and correct treatments, and the time in the 
presence of cancer is a critical variable for survival and, when possible, for 
healing. On the other side, hospitals have a high cost with these approaches 
that require appropriate equipment and specialized personnel, which in 
some regions are scarce or overload of work because of shrinking public lab 
and hospital budgets.  
New technology is based on artificial intelligence technology and some 
studies show that deep learning can be used for the classification of breast, 
bladder and lung tumors (Khosravi et al., 2018). In particular, the 
development of new, inexpensive and more powerful artificial intelligence 
technologies has made possible the training of larger and more complex 
neural networks. This has resulted in the design of several deep 
convolutional neural networks (CNNs) that are capable of accomplishing 
complex visual recognition tasks. Coudray et al., (2018) show that medicine 
can benefit from deep learning technology by convolutional neural 
networks (CNNs) that not only outperforms other methods, but also 
achieves accuracies to classify the type of cancer that are comparable to 
pathologists for selecting the appropriate therapy. These models maintain 
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their performance when tested on independent datasets of frozen tissues as 
well as on images obtained from biopsies. CNNs have been applied with 
regard to classification of lung patterns on computerized tomography (CT) 
scans, with positive results. This new technology is due to Google 
Corporation that in 2014 wonthe ImageNet Large-Scale Visual Recognition 
Challenge. The ImageNet project is a large visual database designed for use 
in visual object recognition software research. More than 14 million images 
have been hand-annotated by the project to indicate what objects are 
pictured and in at least one million of the images, bounding boxes are also 
provided. ImageNet, developingthe GoogleNet architecture, increased the 
robustness to translation and nonlinear learning abilities by using micro 
architectureunits called inception. Each inception unit includes several 
nonlinear convolution modules at various resolutions (cf., Russakovsky et 
al., 2015). Inception architecture is particularly useful for processing the 
data inmultiple resolutions, a feature that makes this architecture suitable 
for medicine and in particular for pathology tasks. This complex neural 
network has already been successfully adapted to specific types of disease 
classifications like, skin cancers and diabetic retinopathy detection (Esteva 
et al., 2016; Gulshan et al., 2016). Coudray et al., 2018) have developed a 
deep-learning model for the automatic analysis of tumor slides using 
publicly available whole-slide images available in The Cancer Genome 
Atlas (TCGA). These scholars trained inception v3 to recognize tumor in 
lung versus normal tissue. After that, they tested the performance of these 
methods on the more challenging task of distinguishing lung 
adenocarcinoma and lung squamous cell carcinoma. They also evaluated 
the deep-learning model by training and testing the network on a direct 
three-way classification into the three types of images (normal tissue, lung 
adenocarcinoma, lung squamous cell carcinoma). Results of this approach 
are compared to the evaluation of three pathologists (two thoracic 
pathologists and one anatomic pathologist) that independently classify the 
whole-slide images in the test set by visual inspection alone, independently 
of the classification provided by TCGA. Overall, the performance of deep 
learning models was comparable to that of each pathologist. Hence, new 
artificial intelligence technology, based on deep-learning models, can assist 
pathologists in the detection of cancer subtype or gene mutations in any 
cancer type with a save of time and costs; moreover, poor regions, with 
these AI technologies, can also have high benefits by sending the digital 
images to labs of other countries, generating a reduction of current gap in 
healthcare between countries. 
Deep learning for detection of metastases in women with breast cancer 
Breast cancer is the most frequent cancer worldwide among women (see 
tab. 1). Studies based on advanced countries show that the incidence of 
breast cancer has been increasing. It has been postulated that breast cancer 
incidence tends to be higher in more developed countries due to delayed 
childbearing, a higher use of hormone replacement therapy, a higher rate of 
screening, and improved tumor registries. Some studies have also argued 
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that higher income countries may have higher fat diets and an increased 
rate of obesity, both correlated with higher breast cancer incidence rates. In 
general, scholars note that many Western populations have a higher 
incidence rate of breast cancer than regions in Africa and Asia (Coccia, 
2013).  
Breast biopsies, like all types of cancer, are used to diagnose breast 
cancer type, stage and mutations. An accurate breast cancer staging is an 
essential task performed by pathologists to inform clinical management. 
For instance, evaluation of the extent of cancer spread by histopathological 
analysis of sentinel axillary lymph nodes is an important part of breast 
cancer staging. The sensitivity of sentinel axillary lymph nodes evaluation 
by pathologists, however, is sub-optimal because some studies show that 
pathology review by experts changed the nodal status in 24% of patients 
(Ehteshami-Bejnordi et al., 2017). This effect is due to the difficulty of the 
process of decision making of human behavior. Moreover, sentinel axillary 
lymph nodes evaluation is time-consuming and has a certain cost. In short, 
the high cost of exams and a period of more than one month to have breast 
cancer type, stage, etc. to decide the appropriate therapy, it can affect 
results of therapeutic treatments and survival of patients.  
The application of Artificial Intelligence (AI) technology with deep 
learning algorithms to whole-slide pathology images canpotentially 
improve diagnostic accuracy of breast cancer and metastases (Lamy et al., 
2019). Some scholars have assessed the performance of automated deep 
learning algorithms at detecting metastases in tissue sections of lymph 
nodes of women with breast cancer and compared results with 
pathologists’ diagnoses. In the setting of a challenge competition, some 
deep learning algorithms achieved better diagnostic performance than a 
panel of 11 pathologists participating in a simulation exercise designed to 
mimic routine pathology workflow; in short, algorithm performance was 
comparable with an expert pathologist interpreting whole-slide images 
without time constraints (Ehteshami-Bejnordi et al., 2017). Hence, this 
experiment has shown that deep learning algorithms couldidentify 
metastases in sentinel axillary lymph nodes slides with 100% sensitivity, 
whereas 40% of the slides without metastases could be identified as such. 
This approach can significantly reduce the workload of pathologists and 
improve the management decisions on whether or not to administer a 
therapy, perform a surgical intervention, etc. Overall, then, this interesting 
result shows the potential of AI applied in cancer imaging for detection of 
lymph node metastases in women with breast cancer to improve processes 
of diagnosis and therapy of this and other critical cancers (cf., Ehteshami 
Bejnordi et al., 2017).  
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Statistical analyses of evolutionary trajectories of AI technology in cancer 
imaging (lung, breast and thyroid).  
 
 
Figure 3. Evolutionary trends of number of article about AI technology per different types 
of cancer (lung, breast, and thyroid) over 1996-2018 period. 
 
Table 2. Estimated relationships of AI in articles per different types of cancer on time 
(Exponential model, 1996-2018 period). 
Note: Dependent variable: Number of articles about the terms Artificial intelligence per 
different types of cancer; explanatory variable is time; ***= p-value< .001 
 
 
Figure 4. Evolutionary trends of number of article about deep learning algorithms per 
different types of cancer (lung, breast, and thyroid) over 1996-2018 period. 
 Lung cancer Breast cancer Thyroid cancer 
Constant λ0 1.000E-013 1.000E-013 1.000E-013 
(St. Err.) (0.00) (0.00) (0.00) 
Coefficient λ1 0.093*** 0.083*** 0.067*** 
(St. Err.) (0.008) (0.006) (0.008) 
F 127.46 186.63 72.34 
Sig.  0.001 0.001 0.001 
R2 adj.  0.85 0.89 0.76 
(St. Err. of the Estimate) (0.28) (0.21) (0.28) 
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Table 3. Estimated relationships of deep learning articles per different types of cancer on 
time (Exponential model,1996-2018 period) 
Note: Dependent variable: Number of articles about the terms Deep Learning per different 
types of cancer; explanatory variable is time; ***= p-value< .001 
 
   
Figure 5. Exponential curves of the number of articles about deep learning per different 
types of cancer (lung, breast, thyroid) on time, 1996-2018 period 
 
Table 4. Rates (per cent)of evolutionary pathways (based on exponential growth)of 
artificial intelligence and deep learning in lung, breast and thyroid cancer from 1996 to 
2018 
Rates of growth 
Artificial 
Intelligence 
and lung 
cancer 
Artificial 
Intelligence 
and 
breast cancer 
Artificial 
Intelligence 
and 
thyroid cancer 
Deep 
learning 
and 
lung cancer 
Deep 
learning 
and 
breast cancer 
Deep learning 
and 
thyroid 
cancer 
r exponential 9.899 8.119 6.803 10.489 11.687 9.987 
 
Figures 3-4 show that the evolution of AI in oncology has exponential 
patterns of growth started in 1990s and ongoing, with an acceleration 
mainly for lung cancer (cf., Fig. 5). Statistical analysis based on regression 
analysis shows that R2 adjusted of models indicates that more than 85% of 
variation in production of articles in AI per different types of cancer can be 
attributed (linearly) to the time as predictor (Tab. 2-4). In particular, 
estimated relationships and exponential rates of growth suggest that AI in 
cancer imaging of breast and lung have a faster growth than thyroid cancer.  
A main finding of this study is the recognition that, since the late 1990s, 
the sharp increase of technological trajectories of AI technology applied in 
cancer imaging seems to be driven by high rates of mortality of some types 
of cancers (e.g., lung and breast) in order to find techniques for a more 
accurate detection, characterization and monitoring to apply efficiently 
anticancer therapies that increase the progression-free survival of patients: 
the so-called mortality-driven technological trajectories in AI (cf., Coccia & 
 Lung cancer Breast cancer Thyroid cancer 
Constant λ0 1.000E-013 1.000E-013 1.000E-013 
(St. Err.) (0.00) (0.00) (0.00) 
Coefficient λ1 0.091*** 0.094*** 0.082*** 
(St. Err.) (0.005) (0.005) (0.007) 
F 302.55 317.25 138.49 
Sig.  0.001 0.001 0.001 
R2 adj.  0.92 0.93 0.86 
(St. Err. of the Estimate) (0.18) (0.18) (0.23) 
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Wang, 2014; Coccia, 2016). These ground-breaking technological trajectories 
of AI are paving new directions and clinical challenges, creating the 
foundations for a revolution in medicine that may lead to more effective 
diagnostic equipment in clinical settings in the not-too-distant future for a 
paradigm shift in clinical practice of pathology. 
 
5. Limitations 
The results and arguments of this study are of course tentative. In fact, 
the phenomenon is complex and analyses here are not sufficient to explain 
the pros and cons of the patterns of AI in cancer imaging, since we know 
that other things are often not equal over time and space. This study may 
form a ground work for development of more sophisticated studies and 
theoretical frameworks. Future efforts in this research field should provide 
more statistical evidence to substantiate the theoretical framework here. To 
reiterate, the study here is exploratory in nature and there is need for much 
more detailed research to shed further theoretical and empirical light on 
technological trajectories supporting the clinical challenges and 
applications of AI technology in cancer imaging. This analysis shows 
general pathways of the evolution of AI in oncology, however the 
evolution of AI technology in medicine is a non-trivial exercise because it 
depends on the behavior of other technologies and manifold factors of 
socioeconomic systems. In this context, Wright (1997, p.1562) properly 
claims that: “In the world of technological change, bounded rationality is 
the rule.”  
 
6. Discussion and conclusion 
Bi Wenya et al., (2019) argue that cancer offers a unique context for 
medical decisions based on variegated forms of disease, individual 
condition of patients, their ability to receive treatment, and their responses 
to treatment (cf., Rosenberg, 1969; Arthur, 2009; McNerney et al., 2011). 
Clinical challenges are in the accurate detection, stage, type and sub-type of 
cancers. Radiographic evaluation of cancer most commonly reliesupon 
visual analysis of imaging, the interpretations of which may be augmented 
by advanced computational analyses. The new technology of artificial 
intelligence (AI) can improve the interpretation of cancer imaging by 
pathologists to detect volumetric delineation of tumors over time, 
mutations, and diffusion on other organs. AI may support the clinical 
process of interpretation of images to shift the clinical workflow of 
pathologists towards management decisions on whether or not to 
administer an intervention, and/or anticancer drugs, etc. 
In medicine, radiology, having converted to digital images about 30 
years ago, is well-positioned to deploy AI for diagnostics. Several studies 
have shown considerable opportunity to support radiologists in evaluating 
a variety of scan types, including mammography for breast lesions, 
computed tomographic scans for pulmonary nodules and infections, and 
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magnetic resonance images for brain tumors including the molecular 
classification of brain tumors. With conversion to digital images, radiology 
reduced costs eliminating film, chemicals, developers, and storage of the 
films. Moreover, radiology departments also solved problems related to 
loss of films and transport of films to where they are needed, for example, 
in operating rooms, emergency departments, and intensive care units. In 
short, digital images using computers have improved the quality, safety, 
and efficiency of radiologists in the management of disease. 
Pathology, by contrast to radiology, has been late to adopt digital 
imaging and computer-assisted diagnostic technologies. The emergence of 
AI in health care, the reduced costs of digital data, and the availability of 
usable digital images are now in alignment for digital pathology to 
succeed. 
However, there are some barriers to the technological diffusion of AI in 
some medical fields. A major unresolved issue is how AI will be 
implemented in routine clinical practice. Numerous intertwined problems 
will have to be addressed to overcome several significant obstacles for the 
diffusion of AI in pathology and other branches of medical science.  
Firstly, digital pathology based on AI may likely be costly at the initial 
phase of diffusion of this new technology owing to additional workflow, 
including personnel, AI must demonstrate improved efficiency, quality, 
and safety. These issues are the first and immediate barriers to a broad 
application of AI in pathology and clinical practice. However, benefits will 
inevitably come from the use of AI with digital images and multiple data 
sets, for example, integrating genomic data and radiologic images to 
further enhance the value of combined data utilization for the overall 
health care system. Recent examples with skin lesions, diabetic retinopathy, 
and radiology detection have highlighted the potential that AI provides to 
aid clinicians to improve quality, safety and diagnosis (Gulshan et al., 2016; 
Esteva et al., 2016). 
Secondly, the cost of new technological devices is an economic barrier. 
This cost is associated to the efficacy and efficiency of AI in pathology that 
have to be clearly demonstrated to government and third-party payers 
(e.g., insurance companies) developing reimbursement strategies. Although 
some reimbursement codes exist for computational analyses in the USA, 
they are not widely used and often are rejected. With US national health 
care reimbursement trends moving to quality and safety metrics, the 
recognition of AI technology as part of reimbursement strategies that 
reward value-based care, rather than fee for service value-based care, 
would provide important incentives to develop and implement validated 
algorithms of AI in clinical practice. 
Thirdly, the critical factor for AI technology is human capital and 
education that will be the greatest challenge and will require the longest 
period to address. AI and other computational methods must be integrated 
into all training programs of the schools of medicine worldwide. Future 
generations of pathologists and physicians must have technical skills 
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comfortable to use digital images and other data in combination for 
accurate diagnosis.  
Overall, then, the promise of AI in health care is the delivery of 
improved quality and safety of care with the great potential of reducing the 
inequality in the access to healthcare sector between people within poor 
and rich countries. Put otherwise, AI technology in medicine can increase 
the democratization of the health care system, and it can potentially 
provide value in many economic sectors generating benefits for an 
industrial and corporate change based on this new technological paradigm. 
For instance, radiologists can now read imaging studies from anywhere in 
the world at their home institution/office, bringing expert care to parts of 
the world that previously had limited expertise. Pathology has the 
opportunity to do the same with digital imaging and AI combined with 
ICTs can permit rapid and accurate local care, also in developing countries 
where there is a high burden of diseases and low medical equipment. 
To conclude, deep learning and in general AI have the opportunity to 
assist pathologists and physicians by improving the efficiency of their 
work, standardizing quality, and providing better prognostication. 
Although workflow of pathologists and other physicians is likely to change 
with AI technology, the contributions of pathologists, and in general of 
humans, to patient care will continue to be critically important to treat 
diseases. Finally, most studies evaluating AI in oncology and other 
branches of medicinal sciences to date have not been vigorously validated 
for reproducibility and generalizability of results. Further research is 
necessary in applied research to determine the feasibility of applying AI in 
the clinical setting and to determine whether use of the AI could lead to 
improved care and outcomes compared with current technologies and 
medical assessments. Overall, then, the technological change based on 
technological paradigm shift of AI in medicine seems to be started to push 
regional and national economies in the next future. 
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